XSHG
603538
Market cap1.50bUSD
Oct 09, Last price
28.45CNY
1D
-3.43%
1Q
-7.87%
IPO
114.65%
Name
Ningbo Menovo Pharmaceutical Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Ningbo Menovo Pharmaceutical Co., Ltd. operates across the full spectrum of pharmaceutical activities, encompassing the research, development, production, and distribution of medicinal products. Their extensive product line features Active Pharmaceutical Ingredients (APIs), intermediate chemicals, and finished drug formulations. These offerings are designed to address a wide range of therapeutic areas, including cardiovascular, central nervous system, respiratory, oncological, anti-infective, digestive, and geriatric disorders, as well as antiviral treatments. The company commenced operations in 2004 and maintains its principal place of business in Ningbo, China.
Key people
Gaofeng Ying
Finance Director, Secretary of the Board, Director · since 2021
Chengzhi Yao
Chairman of the Board, General Manager · since 2018
Jian Xu
Deputy General Manager · since 2019
Fang Yao
Director · since 2021
Hongjun Bei
Independent Director · since 2024
Jie Wei
Independent Director · since 2024
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||